ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RAPH Raphael Pharmaceutical Inc (QB)

1.65
0.00 (0.00%)
03 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Raphael Pharmaceutical Inc (QB) USOTC:RAPH OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.65 0.0161 1.80 0.00 18:15:23

Quarterly Report (10-q)

14/11/2022 4:53pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One) 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to            

 

Commission file number: 000-53002

 

Raphael Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   26-0204284
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

4 Lui Paster Street

Tel Aviv-Jaffa, Israel 6803605

(Address of principal executive offices)

(Zip Code)

 

(+972) 52-775-5072

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of November 14, 2022 : 15,624,040

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
  PART I  
Item 1. Financial Statements F-1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 1
Item 3. Quantitative and Qualitative Disclosures About Market Risk 6
Item 4. Controls and Procedures 6
     
  PART II  
Item 1. Legal Proceedings 7
Item 1A. Risk Factors 7
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 7
Item 6. Exhibits 8

 

i

 

 

Item 1. Financial Statements 

 

RAPHAEL PHARMACEUTICAL INC. AND ITS SUBSIDIARY

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2022

UNAUDITED

 

U.S. DOLLARS IN THOUSANDS

  

INDEX

 

    Page 
     
Condensed Consolidated Interim Balance Sheets   F-2
     
Condensed Consolidated Interim Statements of Comprehensive Loss   F-3
     
Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity   F-4
     
Condensed Consolidated Interim Statements of Cash Flows   F-5
     
Notes to Condensed Consolidated Interim Financial Statements   F-6 – F-9

 

- - - - - - - - - - -

  

F-1

 

 

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

U.S dollars in thousands (except for share and per share data)

 

   As of
September 30,
   As of
December 31,
 
   2022   2021 
   (Unaudited)   (Audited) 
Assets        
Current assets:        
Cash and cash equivalents  $93   $153 
Other current assets   26    269 
           
Total current assets   119    422 
           
Fixed assets, net   2    
-
 
           
Total assets  $121   $422 
           
Liabilities and stockholders’ equity          
           
Current liabilities:          
Other account payables and accrued expenses   183    272 
Payable to related party   -    22 
           
Total current liabilities   183    294 
           
Stockholders’ equity:          
Common stock, $0.01 par value:
Authorized: 21,020,560 shares at June 30, 2022 and December 31, 2021
          
Issued and outstanding: 15,484,040 and 12,970,540 at September 30, 2022 and December 31, 2021, respectively;   155    130 
Additional paid-in capital   4,705    2,665 
Accumulated deficit   (4,922)   (2,667)
           
Total stockholders’ equity (deficit)   (62)   128 
           
Total liabilities and stockholders’ equity (deficit)  $121   $422 

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-2

 

 

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

U.S dollars in thousands (except for share and per share data)

 

   Nine months ended
September 30,
   Three months ended
September 30,
 
   2022   2021   2022   2021 
   Unaudited   Unaudited 
                
Research and development expenses  $502   $552   $332   $161 
                     
General and administrative expenses   1,711    503    1,094    257 
                     
Operating loss   2,213    1,055    1,426    418 
                     
Total financial expense (income), net   42    3    17    (2)
                     
Net loss   2,255    1,058    1,443    416 
                     
Basic and diluted net loss per share
   0.16    0.09    0.10    0.03 
                     
Weighted average number of shares of common stock used in computing basic and diluted net loss per share
   13,921,106    10,811,014    15,061,902    12,131,663 

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-3

 

 

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

 

   Common stock   Additional paid-in   Accumulated   Total 
   Number   Amount   capital   deficit   equity 
                     
Balance as of January 1, 2022   12,970,540   $130   $2,665   $(2,667)  $128 
                          
Issuance of common stock and warrants   975,000    10    502    
-
    512 
Issuance of common stock in exchange for services   280,000    3    287    
-
    290 
Net loss   -    
-
    
-
    (812)   (812)
                          
Balance as of June 30, 2022   14,225,540    143   $3,454   $(3,479)  $118 
                          
Issuance of common stock and warrants   56,000    1    62    
-
    63 
Issuance of common stock in exchange for services   1,202,500    11    1,189    -    1,200 
Net loss   -    
-
    
-
    (1,443)   (1,443)
                          
Balance as of September 30, 2022   15,484,040    155   $4,705   $(4,922)  $(62)

 

   Common stock   Additional paid-in   Accumulated   Total 
   Number   Amount   capital   deficit   equity 
                     
Balance as of January 1, 2021 (*)   9,459,253   $9   $991   $(1,043)  $(43)
                          
Issuance of share capital   1,542,497    2    368    
-
    370 
                          
Effect of reverse recapitalization transaction   1,051,028    1    505    
-
    506 
                          
Net loss   -    -    -    (642)   (642)
                          
Balance as of June 30, 2021   12,052,778   $12   $1,864   $(1,685)  $191 
                          
Issuance of share capital   90,012    (**)    100    -    100 
                          
Net loss   -    -    -    (416)   (416)
                          
Balance as of September 30, 2021   12,142,790   $12   $1,964   $(2,101)  $(125)

 

(*)Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the reverse recapitalization transaction and to reflect adjustment to the share par value (refer to Note 1a).
(**)Represents amount less than $1

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-4

 

 

 RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S dollars in thousands

 

   Nine months Ended
September 30,
 
   2022   2021 
Cash flows from operating activities        
         
Net loss  $(2,255)  $(1,058)
Adjustments to reconcile net loss to net cash used in operating activities:          
           
Share-based payment in exchange for services   1,490    
-
 
           
Changes in:          
Other current assets   243    203 
Account payables   40    140 
           
Net cash used in operating activities   (482)   (715)
           
Cash flows from investing activities          
           
Purchase of fixed assets   (2)   
-
 
           
Net cash provided by investing activities   (2)   
-
 
           
Cash flows from financing activities          
           
Receipt of a loan   
-
    174 
Proceeds from issuance of common stock and warrants   424    470 
Cash acquired in the reverse recapitalization   
-
    13 
Net cash provided by financing activities   424    657 
           
Change in cash and cash equivalents   (60)   (58)
Cash and cash equivalents at the beginning of the period   153    95 
           
Cash and cash equivalents at the end of the period  $93   $37 
           
Supplement disclosure of non-cash activities:          
Current assets (excluding cash and cash equivalents)   -    (531)
Current liabilities   -    38 
Reverse recapitalization effect on equity   -    506 
Cash acquired in connection with reverse recapitalization transaction   -    13 

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

F-5

 

 

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

 

NOTE 1:- GENERAL

 

  a.

Raphael Pharmaceutical Inc (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.

 

On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.

 

On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding Common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share.

 

On May 14, 2021, Raphael and the Company, completed the Share Exchange pursuant to which 9,459,253 common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding common stock of the Company immediately after the Share Exchange while the Company’s shareholders hold, following the Share Exchange, 1,051,028 common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company.

 

The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.

     
  b. Going concern and management plans

 

The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of September 30, 2022, the Company’s accumulated deficit was $4,922. The Company has funded its operations to date primarily through equity financing and the issuance of a loan.  Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.

 

F-6

 

 

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

 

NOTE 1:- GENERAL (Cont.)

 

Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.

 

Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. In the event the Company is unable to have its loan converted as planned or its repayment date deferred, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. If such sufficient financing or payment deferral is not received timely, the Company would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.

 

 NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

 

These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2021. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2021, are applied consistently in these consolidated interim financial statements.

 

NOTE 3:- UNAUDITED INTERIM FINANCIAL STATEMENTS

 

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

 

NOTE 4:- SHAREHOLDERS’ EQUITY

 

  a. On March 2, 2022, the Company raised $10 and issued 50,000 shares of common stock and 30,000 warrants to purchase common stock at an exercise price of $1.25 per share to certain investors of the Company. The warrants were classified as equity and are exercisable until February 28, 2023.

 

  b. On March 15, 2022, the Company issued 270,000 shares of common stock and 180,000 warrants to purchase common stock at an exercise price of $1.13 per share to Company’s service provider in consideration of past services at the amount of $150. The warrants were classified as equity and are exercisable until December 31, 2023.

 

F-7

 

 

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

 

NOTE 4:- SHAREHOLDERS’ EQUITY (Cont.)

 

  c. On April 28, 2022, the Company signed an agreement to raise $50 and to issue 300,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $0.7 per share to certain investor of the Company. The warrants are exercisable until April 30, 2024.The funds were received in July 2022.

 

  d. On April 28, 2022 the Company and a certain investor signed a finder fee agreement according to which the Company will issue to the investor 70,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $0.5 per share. The warrants will be exercisable until April 30, 2024. The agreement will become effective once the investor will provide the Company with an equity investment of $550.
     
  e.

On May 2, 2022, the Company signed several agreements to raise $250 and to issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share to certain investors of the Company. The warrants are exercisable until April 30, 2024. The funds were received in May 2022.

 

In addition, it was agreed that the Company will issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share to a certain investor in consideration of additional $250 if the Company’s stock will be publicly traded on the OTC market prior to August 15, 2022. The additional warrants once issued will be exercisable for 2 years.

     
  f. On June 27, 2022, the Company signed an agreement to raise $50 and to issue 35,000 shares of common stock to certain investor of the Company.
     
  g. On June 30, 2022, the Company issued 280,000 shares of common stock and 105,000 warrants to purchase common stock at an exercise price of $1.12 per share to Company’s former director for his services. The warrants will be exercisable until June 30, 2024.

 

 

F-8

 

 

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

 

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

 

NOTE 4:- SHAREHOLDERS’ EQUITY (Cont.)

 

  h. On July 5, 2022 the Company singed several agreements with it’s executive officers:

 

1.Service agreement with Chief Executive Officer– the Company entered into an agreement with Sheffa Enterprises Inc, a company wholly owned by the Company’s Chief Executive Officer (“CEO”). According to the terms of the agreement, the CEO will provide services to the Company until December 31, 2024 (“termination date”). The fees for his services will be $20 per month starting January 2023 (until January 2023, the fee will remain to be $10 according to June 2019 agreement). In addition, the CEO was granted with 1,000,000 warrants to purchase common stock at an exercise price of $1.12 per share. The warrants exercisable until December 31, 2025. Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CEO a termination fee equal to the lesser of $360 or the monthly fee agreed, for the remaining term of the agreement.

 

2.Service agreement with Chief Financial Officer– The services will consist of financial services, legal advice and serve as a director of the Company. Base compensation will be $12 starting January 2023 (between July 2022 and January 2023 the base compensation will remain $6). In addition, the CFO was granted with 1,000,000 shares of common stock at no cost and 1,000,000 warrants to purchase common stock at an exercise price of $1 per share. The warrants exercisable until December 31, 2025. The agreement is in place until December 31, 2024 (“termination date”). Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CFO a termination fee equal to the lesser of $120 or the monthly fee agreed, for the remaining term of the agreement.

 

3.Consulting agreement with the Chief Technology Officer - the Company entered into an amendment agreement with its Chief Technology Officer (“CTO”). The fees for his services will be $12 per month starting January 2023 (between July 2022 and January 2023 the base compensation will remain $9). According to the terms of the agreement, the CTO will provide consulting services to the Company until December 31, 2023 (“termination date”). In addition, the CTO was granted with 990,000 warrants to purchase common stock at an exercise price of $0.01 per share. The warrants exercisable until July 5, 2024. Furthermore, the CTO will receive 15% of the Company’s net royalties’ from worldwide sales of any of the Company’s cannabis-based medical indications treating COVID-19, and will receive 15% of the net royalty’s income the Company will get for its medical cannabis indication molecules based, for treating Rheumatoid Arthritis (RA) once the Company starts generating revenues. The CTO will be granted with additional 350,000 warrants to purchase common stock at an exercise price of $0.01 per share if the Company will apply for any clinical trial of cannabis based treatment, or will begin any other new cannabis related research. Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CTO a termination fee equal to the fees that were paid or payables to him for three years pursuant to this agreement.

 

i.On July 27, 2022, the Company issued 100,500 shares of common stock to Wolc in connection with the services agreement dated October 2020.

 

j.On September 8, 2022, the Company issued 56,000 shares of common stock to certain investor of the Company pursuant to a share purchase agreement for total consideration of $63.

 

k.On September 8, 2022, the Company issued 102,000 shares of common stock to Company’s service provider for his services. The service agreement is in place until August 2023.

 

F-9

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.

 

On May 14, 2021, Raphael Pharmaceutical Ltd., an Israeli company, and Easy Energy, Inc., a Nevada corporation, completed a share exchange agreement, or the Share Exchange, pursuant to which the shareholders of Raphael Pharmaceutical Ltd. became the holders of 90% of the issued and outstanding share capital of Easy Energy, Inc., while Easy Energy, Inc.’s shareholders hold, following the share exchange, 10% of Easy Energy, Inc. On May 19, 2021, as agreed by the parties to the Share Exchange, Easy Energy, Inc. changed its name to Raphael Pharmaceutical Inc. Unless otherwise mentioned or unless the context requires otherwise, when used in this prospectus, the terms “Raphael,” “Company,” “we,” “us,” and “our” refer to Raphael Pharmaceutical Inc. and its subsidiary, Raphael Pharmaceutical Ltd., or Raphael Israel. References to Easy Energy are to Easy Energy, Inc. Unless otherwise mentioned or unless the context requires otherwise, the information provided in this Quarterly Report on Form 10-Q relates to Raphael Israel.

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

 

  the regulatory pathways that we may elect to utilize in seeking U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and other regulatory approvals, if any;
     
  obtaining (and the cost thereof) FDA and EMA approval of, or other regulatory action in Europe or the United States and elsewhere with respect to our product candidates;
     
  the commercial launch and future sales of our product candidates and our advancement of product candidates for other indications in our pipeline;
     
  the potential cost of our rheumatoid arthritis product candidate, or RA and RA product candidate, respectively, for patients;
     
  our expectations regarding the timing of commencing clinical trials;

 

1

 

 

  our expectations regarding the supply of the active pharmaceutical ingredient for our product candidates;
     
  third-party payor reimbursement for our product candidates;
     
  our estimates regarding anticipated expenses, capital requirements and our needs for additional financing;
     
  completion and receiving favorable results of clinical trials for our product candidates; and
     
  the filing by us, and the subsequent issuance of patents to us, by the U.S. Patent and Trademark Office and other governmental patent agencies.

  

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. For a discussion of these and other risks that relate to our business and investing in our common stock, you should carefully review the risks and uncertainties described in this Quarterly Report on Form 10-Q, and those described from time to time in our future reports filed with the Securities and Exchange Commission. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

 

Overview

 

We are a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD, oil. Unless indicated otherwise, we plan on using oil derived from cannabidiol, or CBD, strains with low levels of Tetrahydrocannabinol, or THC. All references to the use of CBD in our product candidates refer to CBD strains with less than 0.3% of THC.

 

We are currently in the pre-clinical development stage for our lead product candidate, our rheumatoid arthritis, or RA, product candidate for the treatment of RA. In addition, we are aiming to develop a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to COVID-19, or our COVID-19 product candidate, which may be based on data or studies related to our RA product candidate. Our goal is to become a leader in development of CBD oil-based pharmaceutical drug products for the treatment of indications in which we believe there is a high unmet medical need in a range of disorders, including those related to inflammation in the body, including RA and COVID-19.

 

The Company was incorporated in the State of Nevada in May 2007 and was formerly known as Easy Energy, Inc. On May 14, 2021, Easy Energy and Raphael Israel completed the Share Exchange, as a result of which, Raphael Israel’s shareholders own 90% of our Company and Easy Energy’s shareholders hold the remaining 10%. Raphael Israel was incorporated in 2019 in the State of Israel and has focused to date on developing its lead product candidate for the treatment of RA. Easy Energy did not have any ongoing business or operations before the Share Exchange and following the Share Exchange we adopted Raphael Israel’s business plan.

 

Initially, we intend to obtain approvals for our product candidates from the FDA and Medical Cannabis Unit of the Ministry of Health of Israel. Upon obtaining FDA approvals, or in the event that we are not successful in obtaining such approvals, we intend to apply for EMA and other countries’ governmental regulatory agencies approvals for our product candidates. If we are successful in obtaining FDA approvals for our product candidates, we intend to enter into royalty agreements with good manufacturing practice, or GMP, approved medical manufactures and distributors, having them using our medical formulas strains for the purpose of growing, cultivating, manufacturing, and distributing Raphael Pharmaceutical medical indications in their designated territories. 

 

2

 

 

Critical Accounting Policies

 

Our financial statements are prepared in accordance with US GAAP. There are no critical accounting estimates for the years ended December 31, 2021 and 2020. Also, please see Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies. 

 

Results of Operations

 

Three months ended September 30, 2022 compared to the three months ended September 30, 2021

 

Revenues. We had no revenues during the three months ended September 30, 2022 and September 30, 2021.

 

Research and Development Expenses. Our research and development expenses totaled $332,000 for the three months ended September 30, 2022, representing a increase of $171,000, or 106%, compared to $161,000 for the three months ended September 30, 2021. The increase was primarily attributable to expenses recorded as a result of issuance of shares of common stock to a service provider of the Company.

  

General and Administrative Expenses. Our general and administrative expenses totaled $1,094,000 for the three months ended September 30, 2022, representing an increase of $837,000, or 325%, compared to $257,000 for the three months ended September 30, 2021. The increase was primarily due to expenses recorded as a result of issuance of shares of common stock to an executive officer of the Company in connection with his engagement with the Company.

 

Operating Loss. Our operating loss totaled $1,426,000 for the three months ended September 30, 2022, representing an increase of $1,008,000, or 241%, compared to $418,000 for the three months ended September 30, 2021.

 

Financial Expense/(Income). We recognized financial expense of $17,000 for the three months ended September 30, 2022, representing an increase of $19,000, or 650%, compared to financial income of $2,000 for the three months ended September 30, 2021. The increase was primarily due to an increase in exchange rate differences.

  

Net Loss. As a result of the foregoing, our net loss totaled $1,443,000 for the three months ended September 30, 2022, representing an increase of $1,027,000, or 246%, compared to $416,000 for the three months ended September 30, 2021.

 

Nine months ended September 30, 2022 compared to the nine months ended September 30, 2021

 

Revenues. We had no revenues during the nine months ended September 30, 2022 and September 30, 2021.

 

Research and Development Expenses. Our research and development expenses totaled $502,000 for the nine months ended September 30, 2022, representing a decrease of $50,000, or 9%, compared to $552,000 for the nine months ended September 30, 2021. The decrease was primarily attributable to expenses recorded as a result of issuance of shares of common stock to a service provider of the Company which were offset by a decrease in pre-clinical trial expenses, mainly due to the conclusion of the pre-clinical study in mice for Company’s RA product candidate in 2021.

  

General and Administrative Expenses. Our general and administrative expenses totaled $1,711,000 for the nine months ended September 30, 2022, representing an increase of $1,208,000, or 240%, compared to $503,000 for the nine months ended September 30, 2021. The increase was primarily due to expenses recorded as a result of issuance of shares of common stock to an executive officer of the Company in connection with his engagement with the Company and due to retirement fees paid in stock to one of the Company’s directors.

 

3

 

 

Operating Loss. Our operating loss totaled $2,213,000 for the nine months ended September 30, 2022, representing an increase of $1,158,000, or 109%, compared to $1,055,000 for the nine months ended September 30, 2021. The increase was primarily due to increased general and administrative expenses for the nine months ended September 30, 2022 compared to the corresponding period in 2021.

 

Financial Expense. We recognized financial expense of $42,000 for the nine months ended September 30, 2022, representing an increase of $39,000, or 1,300%, compared to $3,000 for the nine months ended September 30, 2021. The increase was primarily due to an increase in exchange rate differences.

  

Net Loss. As a result of the foregoing, our net loss totaled $2,255,000 for the nine months ended September 30, 2022, representing an increase of $1,197,000, or 113%, compared to $1,058,000 for the nine months ended September 30, 2021.

 

Liquidity and Capital Resources

 

Since inception, we have funded our operations primarily through our founder’s capital and capital received from Easy Energy. As of September 30, 2022, we had $93,000 in cash and cash equivalents, and have invested most of our available cash funds in ongoing cash accounts.

 

Net cash used in operating activities was $482,000 for the nine months period ended September 30, 2022, compared with net cash used in operating activities of $715,000 for the corresponding period in 2021. The $233,000 decrease in the net cash used in operating activities during the nine months period ended September 30, 2022, compared to the same period in 2021, was primarily the result of a decrease in pre-clinical trial expenses.

 

Net cash used in investing activities was $2,000 for the nine months period ended September 30, 2022, compared with zero net cash used in investing activities for the corresponding period in 2021. The decrease in the net cash provided by investing activities during the nine months period ended September 30, 2022, compared to the same period in 2021, was primarily due to the purchase of laboratory equipment.

 

Net cash provided by financing activities for the nine months period ended September 30, 2022 was $424,000 compared to $657,000 for the same period in 2021. The decrease in net cash provided by financing activities during the nine months period ended September 30, 2022 compared to the corresponding period in 2021 was mainly due to decrease in receipt of loan funds.

 

Off Balance Sheet Arrangements

 

Rambam Research Agreement

 

Pursuant to a research agreement with Rambam Med-Tech Ltd, or Rambam MT, entered into by the parties in July 2019, or the Research Agreement, the Company agreed to fund a research project, to be performed by Rambam MT, with a research plan aimed at identifying the effects of different cannabis strains on the function of immune cells. On October 28, 2020, the Company and Rambam MT agreed to expand the research plan to study the anti-inflammatory activities of cannabis extracts in an RA mouse model. On February 15, 2021, the Company and Rambam MT agreed to further expand the research plan to study the effect of cannabis extracts on the immunopathology of the COVID-19 disease. The initial term of the Research Agreement was 48 months. On October 24, 2022, the Company and Rambam MT entered into a supplement to the Research Agreement, or the Supplement Agreement, pursuant to which the Company exercised an option to extend the Research Agreement by additional two years.

 

Pursuant to the Research Agreement, we agreed to pay Rambam MT $1.4 million in four equal payments, due on the first day of August on each successive year from 2019 through 2022. Pursuant to the Supplement Agreement, we agreed to pay Rambam MT $960,000 plus VAT in four biannual payments from May 2023 through December 2024. Furthermore, in accordance with the terms of the Research Agreement, we and Rambam MT will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Rambam MT agreed not to work, study or develop any technologies with other entities that compete with our work with Rambam MT for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the parties’ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate.

 

4

 

 

Subject to commercial sales of any product candidate using the IP created as a part of the research covered by such agreement, Raphael Israel is required to pay Rambam MT a royalty in an amount equal to 6% of all net sales, subject to certain deductions, such as taxes paid by any purchaser, transportation and shipping costs, and other customary deductions.

 

As of September 30, 2022, the Company has made three of the four equal payments due pursuant to the Research Agreement, for a total amount of $1,050,000.

 

Way of Life Cannabis Agreement

 

In October 2020, Raphael Israel entered into an engagement agreement with Way of Life Cannabis Ltd., or Wolc, pursuant to which, subject to its completing the Share Exchange with Easy Energy, Raphael Israel will be provided with up to 15 liters of CBD oil, from a strain of cannabis during a term of 18 months, to be provided in two to three deliveries of between one to seven milliliters of CBD oil. In accordance with Raphael Israel’s agreement with Wolc, Raphael Israel has agreed to issue to certain persons affiliated with Wolc 3% of Raphael’s issued and outstanding share capital as of the date of the Share Exchange, to be provided in three equal issuances; provided, however, that such persons may elect to receive a cash payment of $100,000 instead of any one issuance of Raphael’s shares. In addition to the issuance of shares, Raphael Israel has also agreed to pay Wolc a royalty fee equal to 15% of the net royalties generated from sales of Raphael Israel’s pharmaceutical drug products that are developed at Rambam hospital in Israel.

 

Except for the above, we have not engaged in any off-balance sheet arrangements, such as the use of unconsolidated subsidiaries, structured finance, special purpose entities or variable interest entities.

 

We do not believe that our off-balance sheet arrangements and commitments have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Current Outlook

 

We have financed our operations to date primarily through proceeds from our founder’s capital and capital received from Easy Energy. We have incurred losses and generated negative cash flows from operations since inception in 2019. To date we have not generated revenue, and we do not expect to generate significant revenues from the sale of our products in the near future.

 

We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date of the financial statements included elsewhere in this prospectus.

 

As of September 30, 2022, our cash and cash equivalents were $93,000. We believe that our existing cash and cash equivalents will not be sufficient to fund our projected cash requirements through September 2023. Therefore, we will require significant additional financing in the near future to fund our operations. We currently anticipate that we will require approximately $1 million for research and development activities over the course of the next 12 months. We also anticipate that we will require approximately $2 million for capital expenditures over such 12-month period, which consists primarily of expenditures for clinical trials and general Company operating costs.

 

In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including: 

 

  our research and development efforts, including our ability to finish research and development projects or product development within the allotted or expected timeline;

 

5

 

 

  the cost, timing and outcomes of seeking to commercialize our products in a timely manner;
     
  our ability to generate cash flows;
     
  economic weakness, including inflation, or political instability in particular foreign economies and markets;
     
  government regulation in our industry, and more specifically, the costs and timing of obtaining regulatory approval or permits to launch our technology in various geographical markets; and
     
  the costs of, and timing for, strengthening our manufacturing agreements for production of our wave energy systems.

  

In addition to the foregoing, based on our current assessment, we do not expect any material impact on our long-term liquidity due to the COVID-19 pandemic. However, we will continue to assess the effect of the pandemic to our operations. The extent to which the COVID-19 pandemic will impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, any restrictions on the ability of hospitals and trial sites to conduct trials that are not designed to address the COVID-19 pandemic and the perceived effectiveness of actions taken in Israel, the United States and Europe and other countries to contain and treat the disease. While the potential economic impact brought by COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital in the future. In addition, a recession or long-term market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

 

Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through our existing cash, cash equivalents and short-term deposits, loans, or debt or equity financings. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our products. This may raise substantial doubts about our ability to continue as a going concern.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures

 

Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures

 

As of September 30, 2022, we conducted an evaluation, under the supervision and participation of management including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

 

Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of September 30, 2022.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

6

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

There have been no material changes to our legal proceedings as described in “Item 3. Legal Proceedings” in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.

 

Item 1A. Risk Factors

 

There have been no material changes to our risk factors from those disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.  

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Set forth below are the sales of all securities by the Company in the three months ended September 30, 2022, which were not registered under the Securities Act of 1933, as amended, or the Securities Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act and/or Regulation S under the Securities Act.

 

On July 5, 2022, the Company signed a service agreement with Sheffa Enterprises Inc. a company wholly owned by the Company’s Chief Executive Officer (“CEO”), pursuant to which the CEO was granted 1,000,000 warrants to purchase common stock at an exercise price of $1.12 per share. The warrants are exercisable until December 31, 2025.

 

On July 5, 2022, the Company signed a service agreement with the Company’s Chief Financial Officer (“CFO”), pursuant to which the CFO was granted 1,000,000 shares of common stock and 1,000,000 warrants to purchase common stock at an exercise price of $1.00 per share. The warrants are exercisable until December 31, 2025.

 

On July 5, 2022, the Company signed an amendment to the service agreement with the Company’s Chief Technology Officer (“CTO”), pursuant to which the CTO was granted with 990,000 warrants to purchase common stock at an exercise price of $0.01 per share. The warrants are exercisable until July 5, 2024.

 

On July 5, 2022, the Company signed an amendment to the service agreement with one of the Company’s directors, pursuant to which the director was granted with 202,000 warrants to purchase common stock at an exercise price of $1.12 per share. The warrants are exercisable until July 4, 2024.

 

On July 27, 2022, the Company issued 100,500 shares of common stock to Wolc in connection with the services agreement dated October 2020 by and among Wolc and the Company.

 

On September 8, 2022, the Company issued 56,000 shares of common stock to certain investors of the Company pursuant to a share purchase agreement for total consideration of $63,000. The funds for the shares were received during September 2022.

 

On September 8, 2022, the Company issued 102,000 shares of common stock to a service provider of the Company for his services.

 

7

 

 

Item 6. Exhibits

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
10.1*   Supplement to Sponsored Research Agreement with Rambam Med-Tech Ltd.
     
31.1*   Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
     
31.2*   Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
     
32.1*   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.
     
32.2*   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

*Filed herewith.

 

8

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  RAPHAEL PHARMACEUTICAL INC.
     
Date: November 14, 2022 By: /s/ Shlomo Pilo                                     
  Name:  Shlomo Pilo
  Title: Chief Executive Officer
(Principal Executive Officer)
     
Date: November 14, 2022 By: /s/ Guy Ofir
  Name: Guy Ofir
  Title:

Chief Financial Officer

(Principal Financial Officer)

 

 

9

 

 

 

 

0.03 0.09 0.10 0.16 10811014 12131663 13921106 15061902 false --12-31 Q3 0001415397 0.01 0.01 21020560 21020560 0001415397 2022-01-01 2022-09-30 0001415397 2022-11-14 0001415397 2022-09-30 0001415397 2021-12-31 0001415397 2021-01-01 2021-09-30 0001415397 2022-07-01 2022-09-30 0001415397 2021-07-01 2021-09-30 0001415397 us-gaap:CommonStockMember 2021-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001415397 us-gaap:RetainedEarningsMember 2021-12-31 0001415397 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001415397 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001415397 2022-01-01 2022-06-30 0001415397 us-gaap:CommonStockMember 2022-06-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001415397 us-gaap:RetainedEarningsMember 2022-06-30 0001415397 2022-06-30 0001415397 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001415397 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001415397 us-gaap:CommonStockMember 2022-09-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001415397 us-gaap:RetainedEarningsMember 2022-09-30 0001415397 us-gaap:CommonStockMember 2020-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001415397 us-gaap:RetainedEarningsMember 2020-12-31 0001415397 2020-12-31 0001415397 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001415397 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001415397 2021-01-01 2021-06-30 0001415397 us-gaap:CommonStockMember 2021-06-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001415397 us-gaap:RetainedEarningsMember 2021-06-30 0001415397 2021-06-30 0001415397 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001415397 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001415397 us-gaap:CommonStockMember 2021-09-30 0001415397 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001415397 us-gaap:RetainedEarningsMember 2021-09-30 0001415397 2021-09-30 0001415397 2020-10-01 2020-10-08 0001415397 2021-05-01 2021-05-14 0001415397 2021-05-14 0001415397 us-gaap:CommonStockMember 2022-03-01 2022-03-02 0001415397 us-gaap:CommonStockMember 2022-03-02 0001415397 us-gaap:CommonStockMember 2022-03-15 0001415397 us-gaap:CommonStockMember 2022-03-01 2022-03-15 0001415397 us-gaap:CommonStockMember 2022-04-01 2022-04-28 0001415397 us-gaap:CommonStockMember 2022-04-28 0001415397 2022-04-28 0001415397 2022-04-01 2022-04-28 0001415397 2022-04-22 2022-05-02 0001415397 us-gaap:CommonStockMember 2022-05-02 0001415397 us-gaap:CommonStockMember 2022-04-22 2022-05-02 0001415397 2022-05-02 0001415397 2022-06-01 2022-06-27 0001415397 us-gaap:CommonStockMember 2022-06-27 0001415397 us-gaap:CommonStockMember 2022-06-01 2022-06-30 0001415397 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-09-30 0001415397 srt:ScenarioForecastMember srt:ChiefExecutiveOfficerMember 2023-01-01 2023-01-31 0001415397 srt:ChiefExecutiveOfficerMember 2022-09-30 0001415397 srt:ScenarioForecastMember srt:ChiefFinancialOfficerMember 2023-01-31 0001415397 srt:ScenarioForecastMember srt:ChiefFinancialOfficerMember 2023-01-01 2023-01-31 0001415397 srt:ChiefFinancialOfficerMember 2022-01-01 2022-09-30 0001415397 srt:ChiefFinancialOfficerMember 2022-09-30 0001415397 srt:ScenarioForecastMember cik0000141539:ChiefTechnologyOfficerMember 2023-01-01 2023-01-31 0001415397 cik0000141539:ChiefTechnologyOfficerMember 2022-09-30 0001415397 cik0000141539:ChiefTechnologyOfficerMember 2022-01-01 2022-09-30 0001415397 2022-07-27 0001415397 us-gaap:CommonStockMember 2022-09-08 0001415397 us-gaap:CommonStockMember 2022-09-01 2022-09-08 0001415397 2022-09-08 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

1 Year Raphael Pharmaceutical (QB) Chart

1 Year Raphael Pharmaceutical (QB) Chart

1 Month Raphael Pharmaceutical (QB) Chart

1 Month Raphael Pharmaceutical (QB) Chart

Your Recent History

Delayed Upgrade Clock